36. The fusion protein of any one of claims 1-29 or 34, or the pharmaceutical composition of claim 32, for use as a medicament.

37. The fusion protein of any one of claims 1-29 or 34, or the pharmaceutical composition of claim 32, for use in the treatment or prophylaxis of an autoimmune disease.

38. The fusion protein or the pharmaceutical composition of claim 37, wherein said autoimmune disease is selected from the group of type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ulcerative colitis and multiple sclerosis.

39. The fusion protein of any one of claims 1-29 or 34, or the pharmaceutical composition of claim 35, for use in the treatment or prophylaxis of transplant rejection or graft-versus-host disease.

40. Use of the fusion protein of any one of claims 1-29 or 34 for the manufacture of a medicament for the treatment of a disease in an individual in need thereof.

41. The use of claim 40, wherein said disease is an autoimmune disease.

42. The use of claim 41, wherein said autoimmune disease is selected from the group of type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ulcerative colitis and multiple sclerosis.

43. The use of claim 40, wherein said disease is transplant rejection or graft-versus-host disease.

44. The use of any one of claims 40 to 43, wherein said individual is a mammal, particularly a human.

~~45. A method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the fusion protein of any one of claims 1-29 or 34 in a pharmaceutically acceptable form.~~

~~46. The method of claim 45, wherein said disease is an autoimmune disease.~~

~~47. The method of claim 46, wherein said autoimmune disease is selected from the group of type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ulcerative colitis and multiple sclerosis.~~

~~48. The method of claim 45, wherein said disease is transplant rejection or graft versus host disease.~~

~~49. The method of any one of claims 45 to 48, wherein said individual is a mammal, particularly a human.~~

~~50.~~45. The fusion protein of any one of claims 1-29 or 34 for use in selective activation of regulatory T cells *in vitro* ~~or *in vivo*~~.

~~51.~~46. The fusion protein of claim ~~50~~45, wherein said activation comprises induction of proliferation of regulatory T cells and/or induction of IL-2 receptor signaling in regulatory T cells.

~~52.~~47. A method for selective activation of regulatory T cells *in vitro* ~~or *in vivo*~~, comprising contacting said regulatory T cells with the fusion protein of any one of claims 1-29 or 34.

~~53.~~48. The method of claim ~~52~~47, wherein said activation comprises induction of proliferation of regulatory T cells and/or induction of IL-2 receptor signaling in regulatory T cells.

~~54. The invention as described hereinbefore.~~